Association Between Fluoroquinolones and Major Adverse Cardiovascular Events: A Systematic Review.
Journal
Cardiology in review
ISSN: 1538-4683
Titre abrégé: Cardiol Rev
Pays: United States
ID NLM: 9304686
Informations de publication
Date de publication:
30 Apr 2024
30 Apr 2024
Historique:
medline:
30
4
2024
pubmed:
30
4
2024
entrez:
30
4
2024
Statut:
aheadofprint
Résumé
Fluoroquinolones (FQs) are routinely administered antibiotics that have demonstrated an increased propensity to cause major adverse cardiovascular events (MACE). We conducted a systematic review aimed to investigate the association between FQ usage and the risk of MACE. A comprehensive literature search was conducted using PubMed, Scopus, and the Cochrane Library from inception to September 2023 to retrieve studies comparing FQ administration with placebo and reporting the occurrence of MACE. Relevant studies that explored the occurrence of MACE, defined as "acute myocardial infarction, stroke, cardiovascular mortality, arrhythmia, or heart failure" with FQ usage were eligible for inclusion. Four studies with a total of 42,808 patients were included. Levofloxacin, moxifloxacin, and gatifloxacin were observed to have an increased propensity to cause MACE, particularly arrhythmias, whereas ciprofloxacin was associated with the lowest risk of causing MACE. Despite the methodological diversity in the included studies, this systematic review uncovered a consistent trend of heightened likelihood of MACE with FQ administration across studies, suggesting that elevated serum concentrations of some FQs may correlate with higher risks of MACE development. This systematic review emphasizes the need for cautious administration of FQs, particularly in patients with a preexisting cardiovascular condition. Routine cardiac monitoring using electrocardiograms is warranted for patients on high doses of FQs to preemptively detect the development of MACE, particularly arrhythmias.
Identifiants
pubmed: 38687013
doi: 10.1097/CRD.0000000000000710
pii: 00045415-990000000-00254
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
Copyright © 2024 Wolters Kluwer Health, Inc. All rights reserved.
Déclaration de conflit d'intérêts
Disclosure: The authors declare no conflict of interest.
Références
Hooper DC, Jacoby GA. Topoisomerase inhibitors: fluoroquinolone mechanisms of action and resistance. Cold Spring Harb Perspect Med. 2016;6:a025320.
Yan A, Bryant EE. Quinolones. In: StatPearls. Treasure Island (FL): StatPearls Publishing; 2023 [cited 2023 Dec 15]. Available at: http://www.ncbi.nlm.nih.gov/books/NBK557777/
Pham TDM, Ziora ZM, Blaskovich MAT. Quinolone antibiotics. Medchemcomm. 2019;10:1719–1739.
Commissioner O of the. FDA. FDA updates warnings for fluoroquinolone antibiotics on risks of mental health and low blood sugar adverse reactions. FDA; 2020[cited 2023 Dec 15]. Available at: https://www.fda.gov/news-events/press-announcements/fda-updates-warnings-fluoroquinolone-antibiotics-risks-mental-health-and-low-blood-sugar-adverse
Gorelik E, Masarwa R, Perlman A, et al. Fluoroquinolones and cardiovascular risk: a systematic review, meta-analysis and network meta-analysis. Drug Saf. 2019;42:529–538.
Pirmohamed M, James S, Meakin S, et al. Adverse drug reactions as cause of admission to hospital: prospective analysis of 18 820 patients. BMJ. 2004;329:15–19.
Bosco E, Hsueh L, McConeghy KW, et al. Major adverse cardiovascular event definitions used in observational analysis of administrative databases: a systematic review. BMC Med Res Methodol. 2021;21:241.
Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71.
Sterne JAC, Savović J, Page MJ, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019;366:l4898.
Ottawa Hospital Research Institute. [cited 2023 Dec 15]. Available at: https://www.ohri.ca/programs/clinical_epidemiology/oxford.asp
Cannon CP, Braunwald E, McCabe CH, et al.; Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 Investigators. Antibiotic treatment of chlamydia pneumoniae after acute coronary syndrome. N Engl J Med. 2005;352:1646–1654.
Chen Q, Liu YM, Liu Y, et al. Orally administered moxifloxacin prolongs QTc in healthy Chinese volunteers: a randomized, single-blind, crossover study. Acta Pharmacol Sin. 2015;36:448–453.
Liang LY, He YC, Li YF, et al. Relationship between antofloxacin concentration and QT prolongation and estimation of the possible false-positive rate. Biomed Pharmacother. 2020;130:110619.
Lapi F, Wilchesky M, Kezouh A, et al. Fluoroquinolones and the risk of serious arrhythmia: a population-based study. Clin Infect Dis. 2012;55:1457–1465.
Abo-Salem E, Fowler JC, Attari M, et al. Antibiotic-induced cardiac arrhythmias. Cardiovasc Ther. 2014;32:19–25.
Liu X, Ma J, Huang L, et al. Fluoroquinolones increase the risk of serious arrhythmias: a systematic review and meta-analysis. Medicine (Baltim). 2017;96:e8273.
Rao GA, Mann JR, Shoaibi A, et al. Azithromycin and levofloxacin use and increased risk of cardiac arrhythmia and death. Ann Fam Med. 2014;12:121–127.
Zambon A, Polo Friz H, Contiero P, et al. Effect of macrolide and fluoroquinolone antibacterials on the risk of ventricular arrhythmia and cardiac arrest: an observational study in Italy using case-control, case-crossover and case-time-control designs. Drug Saf. 2009;32:159–167.
Inghammar M, Svanström H, Melbye M, et al. Oral fluoroquinolone use and serious arrhythmia: bi-national cohort study. BMJ. 2016;352:i843.
Noel GJ, Natarajan J, Chien S, et al. Effects of three fluoroquinolones on QT interval in healthy adults after single doses. Clin Pharmacol Ther. 2003;73:292–303.
Makaryus AN, Byrns K, Makaryus MN, et al. Effect of ciprofloxacin and levofloxacin on the QT interval: is this a significant “clinical” event? South Med J. 2006;99:52–56.
Lipsky BA, Miller B, Schwartz R, et al. Sparfloxacin versus ciprofloxacin for the treatment of community-acquired, complicated skin and skin-structure infections. Clin Ther. 1999;21:675–690.
Mehrzad R, Barza M. Weighing the adverse cardiac effects of fluoroquinolones: a risk perspective. J Clin Pharmacol. 2015;55:1198–1206.
Clark DW, Layton D, Wilton LV, et al. Profiles of hepatic and dysrhythmic cardiovascular events following use of fluoroquinolone antibacterials: experience from large cohorts from the drug safety research unit prescription-event monitoring database. Drug Saf. 2001;24:1143–1154.
Beisswenger C, Honecker A, Kamyschnikow A, et al. Moxifloxacin modulates inflammation during murine pneumonia. Respir Res. 2014;15:82.
Müller-Redetzky HC, Wienhold SM, Berg J, et al. Moxifloxacin is not anti-inflammatory in experimental pneumococcal pneumonia. J Antimicrob Chemother. 2015;70:830–840.
Alexandrou AJ, Duncan RS, Sullivan A, et al. Mechanism of hERG K+ channel blockade by the fluoroquinolone antibiotic moxifloxacin. Br J Pharmacol. 2006;147:905–916.
Milberg P, Hilker E, Ramtin S, et al. Proarrhythmia as a class effect of quinolones: increased dispersion of repolarization and triangulation of action potential predict torsades de pointes. J Cardiovasc Electrophysiol. 2007;18:647–654.
Lazzerini PE, Capecchi PL, Acampa M, et al. Arrhythmic risk in rheumatoid arthritis: the driving role of systemic inflammation. Autoimmun Rev. 2014;13:936–944.
Singh S, Nautiyal A. Aortic dissection and aortic aneurysms associated with fluoroquinolones: a systematic review and meta-analysis. Am J Med. 2017;130:1449–1457.e9.
Research C for DE and. FDA warns about increased risk of ruptures or tears in the aorta blood vessel with fluoroquinolone antibiotics in certain patients. FDA. 2019 Dec 20 [cited 2024 Apr 1]; Available at: https://www.fda.gov/drugs/drug-safety-and-availability/fda-warns-about-increased-risk-ruptures-or-tears-aorta-blood-vessel-fluoroquinolone-antibiotics
Frankel WC, Trautner BW, Spiegelman A, et al. Patients at risk for aortic rupture often exposed to fluoroquinolones during hospitalization. Antimicrob Agents Chemother. 2019;63:e01712–e01718.
Rubinstein E, Camm J. Cardiotoxicity of fluoroquinolones. J Antimicrob Chemother. 2002;49:593–596.
Polgreen LA, Riedle BN, Cavanaugh JE, et al. Estimated cardiac risk associated with macrolides and fluoroquinolones decreases substantially when adjusting for patient characteristics and comorbidities. J Am Heart Assoc. 8074;7:e00.
Owens RC, Nolin TD. Antimicrobial-associated QT interval prolongation: pointes of interest. Clin Infect Dis. 2006;43:1603–1611.
Desai DS, Hajouli S. Arrhythmias. In: StatPearls. Treasure Island (FL): StatPearls Publishing; 2023 [cited 2023 Dec 21]. Available at: http://www.ncbi.nlm.nih.gov/books/NBK558923/
Srinivasan NT, Schilling RJ. Sudden cardiac death and arrhythmias. Arrhythm Electrophysiol Rev. 2018;7:111–117.